Date: 2015-05-20
Type of information: Series D financing round
Company: RegenXBio (USA - MD)
Investors: Venrock (USA - CA) Brookside Capital (USA - MA) Vivo Capital (USA - CA) Deerfield Management (USA - NY) Fidelity BioSciences (USA - MA) a fund managed by Janus Capital Management (USA - CO); Jennison Associates (USA - NY) on behalf of clients; Perceptive Advisors (USA - NY) QVT Financial (USA - NY) Tourbillon Global Ventures; Sectoral Asset Management (Canada) Cormorant Asset Management (USA - MA) Foresite Capital Management (USA - CA) RTW Investments (USA - NY) and two undisclosed blue-chip investment funds
Amount: $70.5 million
Funding type: series D financing round
Planned used: RegenXBio plans to use the proceeds to advance its lead programs through clinical development, build out its clinical and manufacturing infrastructure, expand its team and add to its current pipeline of innovative AAV gene therapies.
Others: * On May 20, 2015, RegenXBio, a leading biotechnology company in gene therapy, announced the successful completion of a heavily oversubscribed $70.5 million Series D financing. The Series D brings the total capital raised since inception to more than $110 million. The Series D was led by new investor Vivo Capital and existing investors Venrock and Brookside Capital. Additional investors participating in the financing include a fund managed by Janus Capital Management LLC; Jennison Associates LLC on behalf of clients; Perceptive Advisors, LLC; QVT Financial LP; Tourbillon Global Ventures; Sectoral Asset Management; Cormorant Asset Management, LLC; Foresite Capital Management, LLC; RTW Investments and two undisclosed blue-chip investment funds. Existing investors, including Deerfield Management and Fidelity Biosciences, also participated in the financing. For the transaction, Chardan Capital Markets, LLC served as the sole placement agent and Gunderson Dettmer served as legal advisor to the company. In association with the financing, Dr. Edgar Engleman, Managing Partner of Vivo Capital, has joined RegenXBio’s board of directors.
Therapeutic area: Rare diseases - Genetic diseases
